B4313
(E/Z)-BCI hydrochloride
≥98% (HPLC)
Synonyme(s) :
(E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one; 3-(cyclohexylamino)-2,3-dihydro-2-(phenylmethylene)-1Hinden-1-one; 2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride, NSC 150117 hydrochloride
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C22H23NO · HCl
Numéro CAS:
Poids moléculaire :
353.89
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
SMILES string
Cl.O=C1C(=Cc2ccccc2)C(NC3CCCCC3)c4ccccc14
InChI
1S/C22H23NO.ClH/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16;/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2;1H
InChI key
JPATUDRDKCLPTI-UHFFFAOYSA-N
Application
(E/Z)-BCI hydrochloride has been used:
- to evaluate the role of the Duox-H2O2-Dusp6 derepression signaling pathway in heart regeneration
- as an MKP-1 inhibitor to investigate the role of MKP-1 on bexarotent-induced effects
- as a dual specificity phosphatase 6 (DUSP6) inhibitor to study its effects on the proliferation of SKOV3 cells
Biochem/physiol Actions
(E/Z)-BCI Hydrochloride is an inhibitor of dual-specificity phosphatase 6 (Dusp6) and Dusp1; hyperactivates FGF signaling.
BCI is an allosteric inhibitor of Dusp6 that acts within the phosphatase domain to prevent the catalytic stimulation of phosphatase activity induced by ERK2 substrate binding. BCI also hyperactivates FGF signaling, since Dusp6 functions as a feedback regulator of FGF signaling.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Guifang Gan et al.
Theranostics, 11(12), 6006-6018 (2021-04-27)
Objectives: Sorafenib is the only FDA-approved first-line target drug for HCC patients. However, sorafenib merely confers 3-5 months of survival benefit with less than 30% of HCC patients sensitive to sorafenib therapy. Thus, it's necessary to develop a sensitizer for
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1
Gui Y, et al.
The Journal of Pain : Official Journal of the American Pain Society (2019)
HE4 Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6
James NE, et al.
Frontiers in Pharmacology, 10, 216-216 (2019)